Clinical Trial Update: Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial is evaluating and optimizing the timing and dosing of vemurafenib in juvenile patients with BRAF V600E–positive refractory histiocytosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Anna Raciborska | Conditions: Histiocytosis | Phase 2 | Status: RECRUITING